Synonyms: GX-I7 | Hyleukin-7 | Il-7 hybrid Fc | NT-I7 | rhIL-7-hyFc | TJ-107
Compound class:
Peptide
Comment: Efineptakin alfa is a long-acting immunoglobulin (Ig) fusion protein composed of recombinant human IL-7 fused to a hybrid Fc (hyFc) region of a human antibody. It comprises two disulphide bond-linked peptide chains. Efineptakin alfa has hematopoietic and immunopotentiating activities. In the oncology setting IL-7 enhances T-cell-mediated anti-tumour immune responses. Efineptakin alfa is being developed by Genexine (in-licensed to I-MAB Biopharma) and NeoImmuneTech. The peptide sequence of efineptakin alfa is claimed in Genexine's patent WO2016200219A1 as sequence 24 and would appear to be referred to as MGM-IL-7-hyFc therein [3].
|
Classification ![]() |
|
Compound class | Peptide |
International Nonproprietary Names ![]() |
|
INN number | INN |
10725 | efineptakin alfa |
Synonyms ![]() |
GX-I7 | Hyleukin-7 | Il-7 hybrid Fc | NT-I7 | rhIL-7-hyFc | TJ-107 |
Database Links ![]() |
|
Specialist databases | |
IMGT/mAb-DB | 820 |
Other databases | |
CAS Registry No. | 2026634-47-7 (source: WHO INN record) |
GtoPdb PubChem SID | 434122158 |
Search PubMed clinical trials | efineptakin alfa |
Search PubMed titles | efineptakin alfa |
Search PubMed titles/abstracts | efineptakin alfa |